AZN.UK

11,396

+2.8%↑

GSK

1,456.5

+2.64%↑

HLN.UK

393.2

+1.73%↑

AZN.UK

11,396

+2.8%↑

GSK

1,456.5

+2.64%↑

HLN.UK

393.2

+1.73%↑

AZN.UK

11,396

+2.8%↑

GSK

1,456.5

+2.64%↑

HLN.UK

393.2

+1.73%↑

AZN.UK

11,396

+2.8%↑

GSK

1,456.5

+2.64%↑

HLN.UK

393.2

+1.73%↑

AZN.UK

11,396

+2.8%↑

GSK

1,456.5

+2.64%↑

HLN.UK

393.2

+1.73%↑

Search

Indivior PLC

Deschisă

735 0.62

Rezumat

Modificarea prețului

24h

Curent

Minim

700.5

Maxim

745.5

Indicatori cheie

By Trading Economics

Venit

63M

66M

Vânzări

-8M

299M

P/E

Medie Sector

369.5

63.778

EPS

0.319

Marjă de profit

22.074

Angajați

1,030

EBITDA

97M

106M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+50.42% upside

Dividende

By Dow Jones

Următoarele câștiguri

24 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.8M

933M

Deschiderea anterioară

734.38

Închiderea anterioară

735

Indivior PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 apr. 2025, 23:55 UTC

Acțiuni populare

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 apr. 2025, 22:50 UTC

Principalele dinamici ale pieței

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 apr. 2025, 21:08 UTC

Câștiguri

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 apr. 2025, 21:00 UTC

Câștiguri

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 apr. 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 apr. 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 apr. 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 apr. 2025, 23:44 UTC

Top știri

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 apr. 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 apr. 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 apr. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 apr. 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 apr. 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 apr. 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 apr. 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 apr. 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 apr. 2025, 22:43 UTC

Top știri
Achiziții, Fuziuni, Preluări

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 apr. 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 apr. 2025, 21:48 UTC

Top știri

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 apr. 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 apr. 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 apr. 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 apr. 2025, 21:04 UTC

Top știri

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 apr. 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 apr. 2025, 20:53 UTC

Câștiguri

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 apr. 2025, 20:52 UTC

Câștiguri

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparație

Modificare preț

Indivior PLC Așteptări

Obiectiv de preț

By TipRanks

50.42% sus

Prognoză pe 12 luni

Medie 1,111.6 GBX  50.42%

Maxim 1,238.392 GBX

Minim 975 GBX

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIndivior PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

6

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.